English
Back
Download
Log in to access Online Inquiry
Back to the Top

NEWS

Candel Therapeutics Showcases Innovative Cancer Therapy Candidates at 16th Annual International Oncolytic Virotherapy Conference (IOVC)
Candel Therapeutics presented three key developments at the 16th Annual International Oncolytic Virotherapy Conference. The highlights include promising data from the CAN-3110 phase 1b trial in recurrent high-grade glioma, showing 3 out of 6 patients surviving over one year after treatment. The trial demonstrated improved survival compared to historical controls, with survival times of 12.2, 13.0, and 18.7 months.
The company also showcased a new multimodal immunotherapy candidate featuring IL-12 and IL-15, which showed significant tumor growth inhibition. Additionally, biopsy analysis revealed dense lymphocyte infiltrates and minimal tumor cells post-treatment, suggesting effective immune system activation
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more
Translate
Report
3080 Views
Comment
Sign in to post a comment
    Spread kindness and love. Life is short. Don’t let greed eat you.
    8164
    Followers
    50
    Following
    93K
    Visitors
    Follow
    Discussing
    Trump 2.0 Era: How will global markets evolve?
    🎙️Discussion: 1. How will tariff policies affect the movement of key assets such as U.S. stocks, gold, and Bitcoin? 2. Given this context, Show More